Abstract 2-Hydroxylated metabolites of estrogen have been shown to have antiangiogenic effects and inhibit tumor cell proliferation, whereas 4-hydroxylated metabolites have been implicated in carcinogenesis. We examined whether polymorphisms in certain genes involved in estrogen metabolism are associated with endometrial cancer risk in a populationbased case-control study with 371 cases and 420 controls. Based on previously published genotype-phenotype correlation studies, we defined variant alleles thought to increase estrogen 2-hydroxylation as presumptively low-risk (CYP1A1 m1 T6235C and m2 Ile 462 Val) and those thought to increase estrogen 4-hydroxylation as high-risk (CYP1A1  m4 Thr   461 Asn, CYP1A2 A734C, and CYP1B1 Leu 432 Val). Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using unconditional logistic regression. Carrying at least one CYP1A1 m1 or m2 variant allele was associated with a decreased risk of endometrial cancer [ORs (95% CIs), 0.64 (0.44-0.93) and 0.54 (0.30-0.99), respectively]. No strong alteration in risk was observed among women with any of the putative high-risk alleles. When CYP1A1, CYP1A2, and CYP1B1 genotypes were combined and ranked by the number of putative low-risk genotypes carried, women with four or five low-risk genotypes had a reduced risk of endometrial cancer (OR, 0.29; 95% CI, 0.15-0.56) compared with women with one or none. No appreciable alteration in risk was observed among women carrying two or three low-risk genotypes. Some of our findings are consistent with the hypothesis that increased estrogen 2-hydroxylation is associated with decreased endometrial cancer risk, but replication of these results is required before any firm conclusions can be reached. 
Introduction
The risk of endometrial cancer is elevated for women in whom levels of estrogens are relatively high, whether the source of estrogen is exogenous (e.g., via hormonal medications) or endogenous (e.g., as a result of obesity; ref. 1) . It is plausible that interindividual variation in genes that govern the activity of enzymes involved in estrogen metabolism may play a role in susceptibility to endometrial cancer.
The principal estrogens in women, estradiol and estrone, undergo oxidative metabolism through hydroxylation at various sites, including 2-and 4-hydroxylation, leading to the formation of catechol estrogens [reviewed in Zhu and Conney (2); Fig. 1 ]. 2-Hydroxylation is the major oxidative pathway, catalyzed mainly by CYP1A2 in the liver (3, 4) and by CYP1A1 in the endometrium (5) and other extrahepatic tissues. In Syrian hamsters, almost 100% of whom develop kidney tumors after exposure to estradiol, 2-hydroxylated estrogens (2-OH estrogens) do not induce tumors (6, 7) . The Omethylation of 2-hydroxyestradiol (2-OH estradiol) forms 2-methoxyestradiol, which is a potent inhibitor of tumor cell proliferation and has antiangiogenic effects (8, 9) . It is currently being evaluated in phase I and II clinical trials of breast and prostate cancers (10) .
In contrast to 2-OH estrogens, there are several reasons why 4-OH estrogens might be important in carcinogenesis.
Although 4-OH estrogens are formed in much smaller amounts than 2-OH estrogens in the liver (3, 4) , 4-OH estradiol may accumulate in target organs, such as the endometrium, when high levels of 2-OH estradiol inhibit the O-methylation of 4-OH estradiol (11, 12) . In CD-1 mice, 4-OH estradiol more strongly induces endometrial adenocarcinoma than does 2-OH estradiol (13) . 4-OH estradiol is as carcinogenic as estradiol in the Syrian hamster kidney (6, 7) , and the ratio of estradiol 4-to 2-hydroxylation increases during tumorigenesis (14) . This pattern is also observed in human uterine leiomyomata compared with normal myometrium (12) . Additionally, 4-OH estradiol (unlike 2-OH estradiol) possesses potent hormonal activity because it activates the estrogen receptor (2) . CYP1B1 is the primary enzyme involved in the 4-hydroxylation of estrone and estradiol (15) , and it is strongly expressed in the endometrium (5) .
The 2-and 4-OH estrogens can be further oxidized to semiquinones and quinones, which can undergo redox cycling, producing reactive oxygen species that may cause oxidative stress, lipid peroxidation, and DNA damage (reviewed in refs. 16, 17) . The 4-OH estrogen quinones, in contrast to 2-OH estrogen quinones, form depurinating DNA adducts, which could potentially be involved in tumor initiation, by producing mutations in critical genes (16) . The enzyme catechol-O-methyltransferase (COMT), which is expressed in various tissues, including the endometrium (18) , transforms catechol estrogens into inactive metabolites and prevents them from entering into redox cycling (19) . In the Syrian hamster, inhibiting COMT activity results in increased kidney tumorigenesis (20) . The quinones can be deactivated by conjugation with glutathione by glutathione S-transferases (GST; ref. 21) , which are expressed in the endometrium (22, 23) .
The genes mentioned above contain several well-characterized polymorphisms. For CYP1A1, these include CYP1A1 m1 (or MspI, T6235C), which has been observed to be associated with a high inducibility phenotype in several (24) (25) (26) (27) (28) but not all (29-31) studies; CYP1A1 m2 (exon 7, A4889G, Ile 462 Val), which may be associated with increased enzyme activity and inducibility (27, 28, (32) (33) (34) , although some studies did not observe this (26, (35) (36) (37) Met substitution due to a G-to-A transition in exon 4 of the COMT gene results in a heat-labile enzyme that is 4-to 5-fold less effective at methylating catechol substrates in vitro (50) . The Met allele has been reported to result in 2-to 3-fold lower levels of methoxyestrogen metabolite formation in one (51), but not another (52), study. Both GSTM1 and GSTT1 have a deletion polymorphism (''null'' allele), which results in a complete lack of enzymatic activity (53, 54) .
We investigated whether the polymorphisms in CYP1A1, CYP1A2, CYP1B1, COMT, GSTM1, and GSTT1 described above, alone and in combination, affect endometrial cancer risk. Table 1 summarizes the polymorphisms, their possible  functional significance based on laboratory studies, and their potential effect on endometrial cancer risk under the hypothesis that increased exposure to 2-OH estrogen might decrease, and increased exposure to 4-OH estrogen might increase, endometrial cancer risk.
Materials and Methods
Study Subjects. Participants from a population-based casecontrol study of endometrial cancer as well as a subset of controls from a population-based breast cancer case-control study [the Women's Contraceptive and Reproductive Experiences Study (CARE) Study (55) ] conducted during the same period are included in this study. Because our endometrial cancer case-control study relied on the use of control women from the CARE study, which specifically studied only Caucasian and African American women, only Caucasian and African American women were recruited for the endometrial cancer study. Eligible case participants included Caucasian and African American female residents of western Washington state ages 50 to 69 years diagnosed with invasive endometrial cancer between January 1, 1994 and December 31, 1995 (King county only) and between July 1, 1997 and December 31, 1999 (King, Pierce, and Snohomish counties). These women were identified through the Cancer Surveillance System, a population-based tumor registry affiliated with the Surveillance, Epidemiology and End Results Program of the National Cancer Institute (56) . Of the 582 eligible cases identified, 472 (81.1%) were successfully interviewed. Blood samples were provided by 383 (65.8%) of the eligible women (81.1% of interviewed women).
Eligible control women included Caucasian and African American female residents of the three-county area during the years the cases were diagnosed, with intact uteri and no prior history of endometrial cancer. They were selected from two sources [random-digit dialing (ref. 57 ; women ages 50-65 years) and random selection from Health Care Financing Administration data files (women ages 66-69 years)] and were frequency matched to the cases by 5-year age group Table 1 . Summary of polymorphisms in CYP1A1, CYP1A2, CYP1B1, COMT, GSTM1, and GSTT1 examined in the current study and the expected direction of effect on risk of the presence of the variant allele under the hypothesis that an increased 2:4-hydroxylation ratio decreases risk of endometrial cancer The data from one control in the earlier case-control study, who was ascertained as a case in the later casecontrol study, was included in both case and control groups; one case was excluded because of poor quality interview data; and four controls provided blood after the genotyping for this study had ended. Additionally, there were only 11 cases and 26 controls who were Hispanic or non-Caucasian, so we were unable to stratify our analyses on racial subgroups. To reduce the possibility of observing spurious results due to population stratification, we restricted our analyses to non-Hispanic Caucasian women, leaving us with a total of 371 cases and 420 controls.
After informed consent, all participants were administered an in-person interview conducted according to a standard protocol. Each participant was asked only about events that occurred before her reference date, which is the date of diagnosis for cases. Controls were assigned a reference date based on the distribution of diagnosis years for the cases. Data were collected on demographic factors; height; weight at different ages; reproductive, contraceptive, and menstrual history; family history of cancer; history of selected chronic conditions; and history of contraceptive and noncontraceptive hormone use. Color pictures of oral contraceptive and hormone replacement therapy pill packs were used to aid recall. Interviews for the endometrial cancer case-control study and the CARE controls were essentially the same. The protocols of both studies were approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center (Seattle, WA).
Genotype Data. Consenting participants provided venous blood samples from which DNA was extracted using a salting-out procedure (58) . We used PCR-RFLP methods for genotyping. We included positive controls with known genotypes and negative controls (reaction mixtures without DNA templates) in each run of our genotype assays. We conducted our pre-PCR work and post-PCR work in separate rooms and used pipette tips fitted with filters to avoid contamination from aerosol. The laboratory staff were blinded to patient characteristics.
All PCR assays were done with the following conditions: a 20 AL reaction contained 1Â PCR buffer (Qiagen, Valencia, CA), 1.5 mmol/L MgCl 2 , 0.5 units Taq DNA polymerase (Qiagen, Valencia, CA), 200 Amol/L deoxynucleotide triphosphates (Roche Diagnostics, Indianapolis, IN), 100 ng DNA, and 100 nmol/L of each primer except for GSTT1 in which 200 nmol/L of each primer was used. The PCR products were digested with 5 units of restriction enzymes per manufacturer's instructions (New England Biolabs, Beverly, MA), separated on an agarose gel, and visualized by UV after staining with ethidium bromide. The CYP1A1 m2 and m4 polymorphisms are 2 bp apart and both affect the recognition sequence of the restriction enzyme NcoI used in the triplex assay for the GSTT1, GSTM1, and CYP1A1 m2 polymorphisms outlined by Bailey et al. (59) . We modified the assay to definitively distinguish between CYP1A1 m2 and m4 polymorphisms using primers 5V-GAAAGG-CTGGGTCCACCCTCT-3V and 5V-CCAGGAAGAGAAA-GACCTCCCAGCGGTC-3V. The second primer creates a HincII restriction enzyme site that cuts when the CYP1A1 m2 allele is G but does not cut when it is an A. The recognition sequence is not affected by CYP1A1 m4 status. CYP1A1 m2 A allele homozygotes are represented as 182-and 151-bp bands on agarose gel, whereas G homozygotes are represented as 182-, 120-, and 31-bp bands; heterozygotes show all bands. Table 2 contains the primer sequences, thermocycling conditions, restriction enzymes, and gel variables for each assay.
Statistical Analyses. For each polymorphism, deviation from Hardy-Weinberg equilibrium was tested using the standard Pearson m 2 test (Stata version 8.2 ''genhwcci'' command). CYP1A1, CYP1A2, and CYP1B1 alleles were defined as low-risk or high-risk based on the results of published functional studies and the hypothesized effect that the variant would have on the ratio of 2-to 4-hydroxylation, with the highest ratio of 2-to 4-hydroxylation considered to represent the lowest risk for endometrial cancer (see Table 1 ). Odds ratios (OR) and 95% confidence intervals (95% CI) for each putative low-risk or high-risk genotype and endometrial cancer were calculated using unconditional logistic regression. Homozygotes and heterozygotes for each of the variant alleles were compared with homozygotes for the wild-type allele. If homozygous variant genotypes occurred too infrequently to allow them to be assessed separately, they were combined with heterozygotes to increase statistical efficiency. For GSTM1 and GSTT1, individuals lacking both copies of the gene (null) are compared with carriers of at least one copy of the gene (present).
We estimated CYP1A1 haplotype frequencies and calculated ORs and 95% CIs to estimate their associations with endometrial cancer risk, using the most common haplotype as the reference category, with the Hplus program (http:// cougar.fhcrc.org/hplus; ref. 60) . This program estimates the probability of carriage of each of the possible haplotypes for each individual and uses this distribution in the estimation of risk. Haplotypes are treated as unobserved latent variables, and estimating equations are constructed by integrating out these latent haplotypes. The haplotype analysis specifies a logistic penetrance function relating haplotypes and covariates with the disease outcome. The coefficients are estimated through generalized estimating equations, integrated over all possible phases for the latent haplotypes via the conditional expectation of the estimating function given the data. One strength of this program is that it incorporates the error generated from estimating haplotypes into the OR and 95% CI estimates. The program has been validated using simulations (60, 61) .
We also combined genotypes, including all the polymorphisms in the genes involved in the 2-and 4-hydroxylation pathways for which we had data (i.e., CYP1A1, CYP1A2, and CYP1B1), to determine whether certain combinations of the putative low-risk and high-risk genotypes were associated with endometrial cancer risk. Each of the polymorphisms was classified as carriage of one or more variant alleles versus none. The genotype combinations were assigned a value that represented the sum of the total number of presumed low-risk genotypes (according to Table 1 ).
To explore whether the possible effect of decreased Omethylation varies by the relative amounts of 2-and 4-OH estrogen produced, COMT genotypes were examined separately by each level of the combined CYP1A1, CYP1A2, and CYP1B1 genotype classification. In addition, we constructed a logistic regression model with a multiplicative term for COMT and the combined genotype. The P was computed for the likelihood ratio test, comparing logistic regression models with and without the multiplicative term. Similar analyses were done to examine any possible modifying effects of the combined CYP gene variable and GSTM1 and GSTT1 null genotypes.
We adjusted our analyses for age. We did not include other characteristics (e.g., reference year, body mass index, hormone replacement therapy use, oral contraceptive use, cigarette smoking, and parity) in our analyses because they did not alter our results for the stratum-specific estimates or those for the combined genotypes by >10%. All tests of statistical significance were two sided.
Results
Characteristics of cases and controls are presented in Table 3 . Women with endometrial cancer were more likely to have had a high body mass index, to have used unopposed estrogens, and never to have given birth. They were less likely to have used oral contraceptives or smoke cigarettes (Table 3) .
Among the controls, genotype frequency distributions for the polymorphisms studied did not deviate to any appreciable extent from expectation predicted by the Hardy-Weinberg equilibrium (Table 4 ). Carrying at least one CYP1A1 m1 C allele was associated with a decreased risk of endometrial cancer (OR, 0.64; 95% CI, 0.44-0.93), as was carrying at least one CYP1A1 m2 Val allele (OR, 0.54; 95% CI, 0.30-0.99; Table 4 ). The homozygous variant genotype was rare for both m1 and m2 variants (present in 2% and <1% of controls, respectively). The presence of the CYP1A1 m4 allele was not associated with endometrial cancer risk (OR, 1.10; 95% CI, 0.67-1.80; Table 4 ), but we were unable to assess whether carriage of the homozygous variant genotype confers risk of endometrial 
cancer because only one case, and no controls, had that genotype. The results from the estimated CYP1A1 haplotypes were nearly identical to those obtained from examining each genotype separately. Carriage of the CYP1A1 m1 C allele was associated with a decreased risk of endometrial cancer without the presence of the m2 and m4 variant alleles, and the risk was further decreased when the m1 C and m2 Val alleles were carried in combination (Table 5) . There was at most a weak elevation in risk associated with the CYP1A2 CC genotype compared with the AA genotype (OR, 1.24; 95% CI, 0.72-2.12) as well as the CYP1B1 Val/Val genotype compared with the Leu/Leu genotype (OR, 1.34; 95% CI, 0.90-1.98; Table 4 ). Carriage of just one of the CYP1A2 C alleles or of the CYP1B1 Val alleles was not associated with endometrial cancer risk. Contrary to our expectations, the COMT Met/Val and Met/Met genotypes were associated with a weakly decreased risk of endometrial cancer compared with the Val/Val genotype [ORs and 95% CIs, 0.78 (0.55-1.10) and 0.75 (0.51-1.11)]. The GSTT1 null genotype was associated with an increased risk of endometrial cancer (OR, 1.55 95% CI, 1.07-2.24), although the GSTM1 null genotype was not ( Table 4) .
The combined genotypes using all of the polymorphisms we assessed in genes involved in estrogen hydroxylation (CYP1A1, CYP1A2, and CYP1B1), ranked by the number of putative low-risk genotypes carried (according to Table 1 ), are shown in Table 6 . The first column lists the number of putative low-risk genotypes carried, and the ''putative lowrisk genotypes'' columns specify which of the putative low-risk genotypes in CYP1A1, CYP1A2, and CYP1B1 were carried (denoted by X in the relevant column). ORs and 95% CIs were calculated using carriage of one or none of the putative low-risk genotypes as the reference group. Carriage of four or five of the putative low-risk genotypes was associated with a reduced risk of endometrial cancer (OR, 0.29; 95% CI, 0.15-0.56), and there was no appreciable alteration in risk among women carrying two or three of the putative low-risk genotypes (Table 6) .
We attempted to explore whether our data would provide evidence that 2-OH estrogens inhibit the O-methylation of 4-OH estrogens (and possibly allow 4-OH estrogens to accumulate) by examining the risk associated with carriage of the low activity COMT allele by the categories of the combined CYP1A1, CYP1A2, and CYP1B1 genotypes. If this were true, we would have expected to observe an increased risk of endometrial cancer associated with carrying the lowactivity COMT Met allele (compared with the Val allele) among women carrying the combined CYP1A1, CYP1A2, and CYP1B1 genotypes that may result in the highest relative 2-OH estrogen levels. Alternatively, it might be expected that the COMT low-activity allele would be associated with an increased risk in the subgroup of women who might have produced the highest relative levels of 4-OH estrogen. Contrary to what we expected, the COMT low-activity allele was not associated with an increased risk of endometrial cancer in any of the subgroups; indeed, there was a suggestion of a decreased risk among women carrying genotype combinations that are thought to result in the lowest 2:4-hydroxylation ratio (carriage of one and none of the low-risk alleles; OR, 0.58; 95% CI, 0.32-1.04; Table 7 ). There was little evidence of any interaction between the combined CYP1A1, CYP1A2, and CYP1B1 genotypes and GSTM1 or GSTT1 genotypes (Table 7) , although the study has limited statistical power to detect such an interaction.
Discussion
Our study sought to examine whether variants in genes involved in catechol estrogen formation and metabolism are associated with endometrial cancer risk. Although we examined the association between eight individual polymorphisms and endometrial cancer risk, we chose not to control for multiple testing because of our strong a priori hypotheses, which were based on biological evidence of the functional significance of the genotypes. We based the interpretation of our results on the magnitude and direction of the ORs, not statistical significance. We hypothesized that endometrial cancer incidence would be relatively lower in women with genotypes that might be associated with inferred higher estrogen 2-hydroxylation and lower 4-hydroxylation and higher among women with an inferred impaired ability to convert the putative high-risk 4-hydroxylated metabolites to less harmful compounds and the 2-hydroxylated metabolites to compounds thought to be protective (see Table 1 ). Specifically, based on experimental evidence indicating that the CYP1A1 m1 and m2 variants might be associated with higher enzyme activity and/or inducibility (24) (25) (26) (27) (28) and therefore possibly increased 2-OH estrogen formation, we hypothesized that they might be associated with a decreased (10) 13 (3) Only estrogen + progestin 121 (33) 176 (42) Unopposed estrogen and estrogen + progestin 46 (13) 41 (10) Unopposed progestin and estrogen + progestin
Only unopposed progestin 6 (2) 3 (1)
*Distributions of characteristics are reported for non-Hispanic Caucasian women only, because there were too few African American and/or Hispanic women (11 cases and 26 controls) to either stratify on or control for race/ethnicity. Therefore, they were excluded from analyses. c Two cases and 14 controls either used sequential oral contraceptives or used unknown oral contraceptives during that time when sequential oral contraceptives were marketed; these data are not included above. bData were missing for body mass index for one case.
x Postmenopausal use of estrogen and progestin hormonal pills or patches for z6 months. Data were missing for four cases and four controls. Because the CYP1A1 m4 Asn allele has been reported to be associated with decreased activity (36, 38), we expected it to be associated with an increased risk, but it was not. Consistent with our results, in a small study (reported in abstract form; 43 cases and 36 controls), possessing at least one CYP1A1 m2 allele was associated with a decreased risk of endometrial cancer (OR, 0.51; 95% CI, 0.13-1.97; ref. 62) . However, in a Spanish hospital-based study of endometrial cancer (80 cases and 60 controls), ORs and 95% CIs associated with the presence of the CYP1A1 m1, m2, and m4 variant alleles were 3.67 (1.21-13.26), 3.67 (1.21-13.26), and 6.36 (1.99-26.5), respectively (63, 64) . ORs (95% CIs) of 0.88 (0.33-2.35) and 1.7 (0.63-4.57) for carriers of the m1 and m2 variant alleles, respectively, were observed in a small Japanese study (38 cases and 31 controls; ref. 65) .
We observed a modest increased risk associated with the CYP1B1 Val/Val genotype. Two other studies have examined the association between this variant and endometrial cancer risk. Although there was no association reported in a nested endometrial cancer case-control study within the Nurses' Health study cohort (222 cases and 666 controls; ref. 66), a Japanese study (113 cases and 202 controls) observed that carriers of the Val/Val genotype were at a 2.5-fold increased risk of endometrial cancer (95% CI, 1.10-5.66; ref. 67). These two studies also reported results for other polymorphisms in the CYP1B1 gene, with inconsistent results.
When alleles from CYP1A1, CYP1A2, and CYP1B1 were combined into genotypes that we hypothesized might be associated with high versus low 2-to 4-hydroxylation ratios and ranked by the number of low-risk genotypes carried, we observed a 71% decreased risk associated with carriage of four and five low-risk genotypes compared with carriage of no more than one. These results suggest that a relative increase in 2-OH estrogen (and a decrease in 4-OH estrogen) might be associated with a decreased risk of endometrial cancer.
We expected that the COMT low-activity allele would be associated with an increased risk of endometrial cancer, Table 4 *HWE could not be tested because the assay detects the presence or absence of the allele, not the number of copies. NOTE: For example, in the first row, with a ''0'' in column 1, 9 (2.4%) cases and 5 (1.2%) controls carried a genotype combination that included no low-risk genotypes at CYP1A1 m1, m2, and m4; CYP1A2 ; and CYP1B1 (designated by a ''-'' in each of those columns). In the second to last row, with a ''5'' in column 1, 3 (0.8%) cases and 7 (1.7%) controls carried a low-risk genotype at all loci (designated by a ''X'' in each of the columns). In the last row, with ''Any 4 and 5'' in column 1, the numbers and frequencies in bold are the sums of all the rows containing genotypes with four and five putative low-risk genotypes. *''X'' in the column indicates the presence of the genotype. Only genotype combinations that were present in the cases or controls are shown. CYP1A2, and CYP1B1, there was a suggestion that the COMT Met allele was associated with a decreased risk just in the group carrying no more than one low-risk genotype (which is possibly the group with the highest level of 4-OH estrogen and the lowest level of 2-OH estrogen). Our study has limited power to detect such an interaction, and these results are presented only for the purposes of generating hypotheses.
The other study to date to examine the association between the COMT Met allele and endometrial cancer risk reported an OR close to 1 (66) . It could be that even a low-activity form of the COMT enzyme might be capable of converting enough of the 2-OH estrogen into 2-methoxyestrogen for it to exert a protective or neutral role with respect to endometrial cancer risk. Alternatively, it has been reported that estradiol can reduce COMT expression through an estrogen receptor -mediated mechanism (68) . Because the majority of women who develop endometrial cancer have relatively high estradiol levels, this possible reduction in COMT expression may outweigh the effect that the Val 158 Met polymorphism has on the relative production of 2-and 4-hydroxylated metabolites. Furthermore, although one study reported decreased methoxyestrogen formation associated with the Met allele in an Escherichia coli expression system and in human breast cancer cell lines (51), another study failed to find such a difference (52) . Finally, the pathways considered in this article may prove to be more complex; in addition to the roles CYP1A1 and CYP1B1 play in the production of catechol estrogens via estrogen hydroxylation, it has been observed that these enzymes can demethylate methoxyestrogens back into catechol estrogens and that methoxyestrogens decrease the production of catechol estrogens by feedback inhibition on CYP1A1 and CYP1B1 (69) . Given that COMT is expressed in the endometrium, it is a promising candidate gene to examine in relation to endometrial cancer risk. It is possible that other polymorphisms in this gene may prove to be more relevant than the one we investigated.
In the study by Esteller et al. (63) , the GSTM1, but not the GSTT1, null genotype was associated with an increased risk of endometrial cancer (OR, 2.01; 95% CI, 0.9-4.2). However, in the current study, only the GSTT1 null genotype was associated with an increased risk (OR, 1.55; 95% CI, 1.07-2.24). Even if one or both of these GST genotypes were truly associated with the risk of endometrial cancer, it is not entirely clear what the mechanistic role of the GSTM1 and GSTT1 enzymes might be. GSTs are probably involved in the deactivation of estrogen-derived quinones (21) , but it is not clear which of the GSTs are involved. A recent report showed that GSTP1 has this capability, and the authors suggest that because the GSTs have overlapping substrate specificity it is likely that other GSTs share this property (70) . In addition, GSTM1 has been observed to deactivate equine catechol estrogen quinones through reduced glutathione conjugation (71) . The GSTs are also involved in catabolism of some environmental carcinogens (such as polycyclic aromatic hydrocarbons in cigarette smoke) that are activated by CYP1A1, CYP1A2, and CYP1B1 (72) . It is possible that an association with polymorphisms in the GST genes as well as the CYP1A1, CYP1A2 and CYP1B1 genes could be due to the role that they play in another metabolic pathway with substrates other than estrogen and its metabolites.
There is no obvious explanation for the inconsistent results observed in studies of the genotypes above and endometrial cancer risk. Given that most of the risk estimates reported to date are based on a few study participants and that the expected true effect of the allele (if any) would be small, sampling variability and low study power is perhaps the most plausible explanation for many of the between-study differences in risk estimates. Another possibility is a combination of (a) a true difference in the relative risk associated with the presence of a particular allele according to the presence or absence of another etiologic factor (e.g., unopposed estrogen use or obesity) and (b) a difference in the prevalence of that other factor in the various populations in which the studies had been conducted. Confounding by race and selection bias may also be issues. Unfortunately, from just the data provided in published reports of these studies, these potential explanations generally cannot be evaluated.
Although our results from the combined CYP1A1 , CYP1A2, and CYP1B1 genotypes are consistent with the hypothesis that a relative increase in estrogen 2-hydroxylation compared with 4-hydroxylation might be associated with a reduced risk of endometrial cancer, our results for COMT do not necessarily provide support for this hypothesis. Our results would be strengthened by additional genotype information, particularly for other common, possibly functional polymorphisms in the genes studied that have been described and characterized since our genotyping for this research began. Other genes of potential interest are CYP3A4 and CYP3A5, involved in hepatic estrogen 2-hydroxylation (73); NAD(P)H:quinone oxidoreductase, involved in preventing catechol estrogen from redox cycling (74) ; and manganese superoxide dismutase, involved in reducing oxidative stress caused by redox cycling (75) . Building multigenic, pathway-based models of endometrial cancer risk could well aid in our understanding of this disease and our understanding of the actions of estrogens and their precursors and metabolites.
